Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine.

Manosuthi W; Butler DM; Chantratita W; Sukasem C; Richman DD; Smith DM

首页> 外文期刊>AIDS Research and Human Retroviruses >Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine.

【24h】

Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine.

机译：感染了HIV 1型CRF01_AE亚型且一线基于奈韦拉平和依非韦伦的方案失败的患者表现出对依曲韦林的相当大的交叉耐药性。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Editor: The nonnucleoside reverse transcriptase inhibitor (NNRTI) class of drugs is a widely used component of highly active antiretroviral therapy, but a low barrier to resistance is a major limitation of this drug class. Etravirine, a new NNRTI, has potent antiviral efficacy against both wild-type and NNRTI-resistant subtype B HIV-1 strains. Rather than one or two mutations conferring resistance to a specific drug, such as nevirapine or efavirenz, resistance to etravirine develops through the accumulation of multiple NNRTI resistance-associated mutations (RAMs), i.e., higher genetic barrier to resistance. Specifically, 17 RAMs have been associated with virologic responses to etravirine use and a relative weighted score has been proposed; 74%, 52%, and 38% patients receiving etravirine achieved viral suppression (<50 copies/ml) in the presence of 0-2, 2.5-3.5, and >3.5 of scores, respectively.5

机译：编辑：非核苷类逆转录酶抑制剂（NNRTI）类药物是高活性抗逆转录病毒疗法的一种广泛使用的成分，但是耐药性低的障碍是该类药物的主要限制。依替韦林是一种新的NNRTI，对野生型和耐NNRTI的B亚型HIV-1毒株均具有有效的抗病毒功效。通过增加多个NNRTI耐药相关突变（RAM）（即更高的耐药遗传障碍）积累了对依特韦林的耐药性，而不是赋予特定药物如奈韦拉平或依非韦伦的耐药性的一两个突变。具体而言，已经有17个RAM与使用依特韦林的病毒学应答有关，并提出了相对加权评分。分别接受0-2、2.5-3.5和> 3.5评分的接受Etravirine的患者分别有74％，52％和38％获得了病毒抑制（<50拷贝/ml）。5

著录项

来源
《AIDS Research and Human Retroviruses》 |2010年第6期|共3页
作者
Manosuthi W; Butler DM; Chantratita W; Sukasem C; Richman DD; Smith DM;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类传染病;
关键词

相似文献

外文文献
中文文献
专利

1. Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. [J] . Manosuthi W, Butler DM, Chantratita W, AIDS Research and Human Retroviruses . 2010,第6期

机译：感染了HIV 1型CRF01_AE亚型且一线基于奈韦拉平和依非韦伦的方案失败的患者表现出对依曲韦林的相当大的交叉耐药性。
2. Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study [J] . Sanjeev Sinha, Kartik Gupta, Srikanth Tripathy, BMC Infectious Diseases . 2017,第1期

机译：在印度患有HIV和结核病感染的抗逆转录病毒初治患者中，基于奈韦拉平和依法韦仑的抗逆转录病毒疗法方案：一项多中心研究
3. Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naive patients with advanced HIV infection. [J] . Manosuthi W, Sungkanuparph S, Vibhagool A, HIV medicine . 2004,第2期

机译：基于奈韦拉平和依非韦伦的高活性抗逆转录病毒治疗方案，适用于未接受过HIV感染的抗逆转录病毒初治患者。
4. The Two First-Line Recommended Antiretroviral Regimens for Naive HIV-Infected Patients: Efavirenz-Based Versus Lopinavir-Ritonavir-Based Haart [C] . R. Manfredi, L. Calza, F. Chiodo International AIDS Conference . 2004

机译：幼稚艾滋病毒感染患者的两种第一线推荐的抗逆转录病毒方案：efavirenz为基于Lopinavir-Ritonavir的HAART
5. Patients Infected with HIV Type 1 Subtype CRF01_AE and Failing First-Line Nevirapine- and Efavirenz-Based Regimens Demonstrate Considerable Cross-Resistance to Etravirine [O] . Weerawat Manosuthi, David M. Butler, Wasun Chantratita, -1

机译：感染了HIV 1型CRF01_AE亚型且一线基于奈韦拉平和依非韦伦的方案失败的患者证明对依曲韦林具有相当大的交叉耐药性
6. Patients Infected with HIV Type 1 Subtype CRF01_AE and Failing First-Line Nevirapine- and Efavirenz-Based Regimens Demonstrate Considerable Cross-Resistance to Etravirine [O] . Manosuthi, Weerawat, Butler, David M., Chantratita, Wasun, 2010

机译：感染了HIV 1型CRF01_AE亚型且一线基于奈韦拉平和依非韦伦的方案失败的患者证明对依曲韦林具有相当大的交叉耐药性

Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine.

摘要

著录项

相似文献

相关主题

期刊订阅